Jefferies Group's HALO Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 26,925 shares of Halozyme Therapeutics, Inc. (HALO) worth $1.81 M, representing 0.01% of the portfolio. First purchased in 2023-Q2, this short-term holding has been held for 7 quarters.
Based on 13F filings, Jefferies Group has maintained this position in HALO for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 26,925 shares. Largest reduction occurred in Q3 2023, reducing 44,250 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2023 | +44,250 | New Buy | 44,250 | $36.07 |
| Q3 2023 | -44,250 | Sold Out | 0 | $0.00 |
| Q4 2023 | +16,504 | New Buy | 16,504 | $36.96 |
| Q1 2024 | -16,504 | Sold Out | 0 | $0.00 |
| Q1 2025 | +12,263 | New Buy | 12,263 | $63.81 |
| Q2 2025 | -12,263 | Sold Out | 0 | $0.00 |
| Q4 2025 | +26,925 | New Buy | 26,925 | $67.30 |
Jefferies Group's Halozyme Therapeutics Investment FAQs
Jefferies Group first purchased Halozyme Therapeutics, Inc. (HALO) in Q2 2023, acquiring 44,250 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Halozyme Therapeutics, Inc. (HALO) for 7 quarters since Q2 2023.
Jefferies Group's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q2 2023, adding 44,250 shares worth $1.6 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 26,925 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $1.81 M.
As of the Q4 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.01% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Halozyme Therapeutics, Inc. (HALO) was 44,250 shares, as reported at the end of Q2 2023.